Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Racks Up Positive Phase III Data For Blincyto And Repatha

This article was originally published in The Pink Sheet Daily

Executive Summary

Company announces positive results from a confirmatory study of bispecific antibody Blincyto, on the heels of unveiling positive new data for PCSK9 inhibitor Repatha in statin-intolerant patients.


Related Content

Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?


Related Companies